Skip to content

Study · Animal study (in vivo) · 2010

11 results

Effects of gamma-glutamyl linker on DPP-IV resistance, duration of action and biological efficacy of acylated glucagon-like peptide-1.

Kerr BD, Flatt PR, Gault VA

Biochemical pharmacology22 Apr 2010Cited by 12 (Europe PMC)

PMID20417187 (opens in a new tab)DOI10.1016/j.bcp.2010.04.021 (opens in a new tab)PepBankPUB-20417187
Publisher pagePubMedAsk about this study
Jump to 11 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In animals, liraglutide given 4 and 8 h before a glucose load significantly lowered plasma glucose.

    In plain wordsIn animals, liraglutide given hours before a glucose load lowered blood glucose.

    Peptide
    Liraglutide
    Outcome
    DecreasePlasma glucose after a glucose load
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Fold lowering of plasma glucose
    1.3 to 1.9 fold
    Lira-gammaGlu and liraglutide, 4 and 8 h before glucose load

    Source sentences

    Summary
    In vivo, Lira-gammaGlu and Liraglutide significantly lowered plasma glucose when administered 4 and 8h prior to a glucose load (1.3-1.9-fold; p<0.05 to p<0.001).
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In animals, twice-daily liraglutide for 14 days significantly decreased food intake.

    In plain wordsIn animals, twice-daily liraglutide for 14 days reduced food intake.

    Peptide
    Liraglutide
    Outcome
    DecreaseFood intake after 14 days
    Study

    n: not reported in source

    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    twice daily · 14 daysAs given in this study.

    Measurements

    Fold decrease in food intake
    1.2 fold
    Lira-gammaGlu and liraglutide

    Source sentences

    Summary
    Twice-daily administration of Lira-gammaGlu and Liraglutide for 14 days significantly decreased food intake (1.2-fold; p<0.05) and plasma glucose (1.1-1.6-fold; p<0.05 to p<0.01) whilst increasing plasma insulin (1.4-1.6-fold; p<0.05).
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In animals, twice-daily liraglutide for 14 days significantly decreased plasma glucose.

    In plain wordsIn animals, twice-daily liraglutide for 14 days lowered blood glucose.

    Peptide
    Liraglutide
    Outcome
    DecreasePlasma glucose after 14 days
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    twice daily · 14 daysAs given in this study.

    Measurements

    Fold decrease in plasma glucose
    1.1 to 1.6 fold
    Lira-gammaGlu and liraglutide

    Source sentences

    Summary
    Twice-daily administration of Lira-gammaGlu and Liraglutide for 14 days significantly decreased food intake (1.2-fold; p<0.05) and plasma glucose (1.1-1.6-fold; p<0.05 to p<0.01) whilst increasing plasma insulin (1.4-1.6-fold; p<0.05).
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In animals, twice-daily liraglutide for 14 days increased plasma insulin.

    In plain wordsIn animals, twice-daily liraglutide for 14 days raised blood insulin.

    Peptide
    Liraglutide
    Outcome
    IncreasePlasma insulin after 14 days
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Endocrine and hormones
    Studied dose
    twice daily · 14 daysAs given in this study.

    Measurements

    Fold increase in plasma insulin
    1.4 to 1.6 fold
    Lira-gammaGlu and liraglutide

    Source sentences

    Summary
    Twice-daily administration of Lira-gammaGlu and Liraglutide for 14 days significantly decreased food intake (1.2-fold; p<0.05) and plasma glucose (1.1-1.6-fold; p<0.05 to p<0.01) whilst increasing plasma insulin (1.4-1.6-fold; p<0.05).
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In animals treated for 14 days, liraglutide markedly improved glucose tolerance.

    In plain wordsIn animals, 14 days of liraglutide clearly improved how well the body handled glucose.

    Peptide
    Liraglutide
    Outcome
    IncreaseGlucose tolerance at 14 days
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 14 daysAs given in this study.

    Measurements

    Fold improvement in glucose tolerance
    1.4 to 3.4 fold
    Lira-gammaGlu and liraglutide

    Source sentences

    Summary
    At 14 days, Lira-gammaGlu and Liraglutide markedly improved glucose tolerance (1.4-3.4-fold; p<0.05 to p<0.001), insulin response to glucose (1.4-1.5-fold; p<0.05), insulin sensitivity (1.3-1.4-fold; p<0.05 to p<0.01), as well as increasing pancreatic insulin content (1.4-fold; p<0.05).
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In animals treated for 14 days, liraglutide improved the insulin response to glucose.

    In plain wordsIn animals, 14 days of liraglutide improved the insulin response to glucose.

    Peptide
    Liraglutide
    Outcome
    IncreaseInsulin response to glucose at 14 days
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Endocrine and hormones
    Studied dose
    Dose not stated · 14 daysAs given in this study.

    Measurements

    Fold improvement in insulin response
    1.4 to 1.5 fold
    Lira-gammaGlu and liraglutide

    Source sentences

    Summary
    At 14 days, Lira-gammaGlu and Liraglutide markedly improved glucose tolerance (1.4-3.4-fold; p<0.05 to p<0.001), insulin response to glucose (1.4-1.5-fold; p<0.05), insulin sensitivity (1.3-1.4-fold; p<0.05 to p<0.01), as well as increasing pancreatic insulin content (1.4-fold; p<0.05).
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In animals treated for 14 days, liraglutide improved insulin sensitivity.

    In plain wordsIn animals, 14 days of liraglutide improved insulin sensitivity.

    Peptide
    Liraglutide
    Outcome
    IncreaseInsulin sensitivity at 14 days
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 14 daysAs given in this study.

    Measurements

    Fold improvement in insulin sensitivity
    1.3 to 1.4 fold
    Lira-gammaGlu and liraglutide

    Source sentences

    Summary
    At 14 days, Lira-gammaGlu and Liraglutide markedly improved glucose tolerance (1.4-3.4-fold; p<0.05 to p<0.001), insulin response to glucose (1.4-1.5-fold; p<0.05), insulin sensitivity (1.3-1.4-fold; p<0.05 to p<0.01), as well as increasing pancreatic insulin content (1.4-fold; p<0.05).
  8. 08AnimalAnimal study (in vivo)Efficacy outcome

    In animals treated for 14 days, liraglutide increased pancreatic insulin content.

    In plain wordsIn animals, 14 days of liraglutide increased the insulin stored in the pancreas.

    Peptide
    Liraglutide
    Outcome
    IncreasePancreatic insulin content at 14 days
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Endocrine and hormones
    Studied dose
    Dose not stated · 14 daysAs given in this study.

    Measurements

    Fold increase in pancreatic insulin content
    1.4 fold
    Lira-gammaGlu and liraglutide

    Source sentences

    Summary
    At 14 days, Lira-gammaGlu and Liraglutide markedly improved glucose tolerance (1.4-3.4-fold; p<0.05 to p<0.001), insulin response to glucose (1.4-1.5-fold; p<0.05), insulin sensitivity (1.3-1.4-fold; p<0.05 to p<0.01), as well as increasing pancreatic insulin content (1.4-fold; p<0.05).
  9. 09LabIn vitro (cells)Activity measurement

    In cells, liraglutide stimulated cAMP production with an EC50 of 0.16 nM, compared with 3.81 nM for GLP-1.

    In plain wordsIn cells, liraglutide triggered cAMP production at a much lower concentration than natural GLP-1.

    Peptide
    Liraglutide
    Outcome
    Not applicablecAMP production potency (EC50)
    Study

    n: not reported in source

    Comparator
    GLP-1
    Outcome group
    Receptor activity and mechanism · Pharmacology
    Studied dose
    Dose not stated

    Measurements

    EC50
    0.16 nM
    liraglutide, cAMP production
    EC50
    3.81 nM
    GLP-1, cAMP production

    Source sentences

    Summary
    plus effective cAMP production (EC(50): 0.15+/-0.11 and 0.16+/-0.11nM, respectively) compared to GLP-1 (EC(50) 3.81+/-0.80nM).
  10. 10LabIn vitro (cells)Efficacy outcome

    In cells, liraglutide increased insulin secretion compared with glucose alone, by 1.5- to 3.0-fold across the tested peptides.

    In plain wordsIn cells, liraglutide increased insulin release compared with glucose alone.

    Peptide
    Liraglutide
    Outcome
    IncreaseInsulin secretion
    Study

    n: not reported in source

    Comparator
    Glucose alone
    Outcome group
    Glycemic control · Endocrine and hormones
    Studied dose
    Dose not stated

    Measurements

    Fold increase in insulin secretion
    1.5 to 3 fold
    GLP-1, Lira-gammaGlu and liraglutide

    Source sentences

    Summary
    GLP-1, Lira-gammaGlu and Liraglutide increased insulin secretion compared to glucose (1.5-3.0-fold; p<0.05 to p<0.001).
  11. 11LabIn vitro (cell-free)Pharmacokinetics

    In lab tests, liraglutide showed enhanced DPP-IV resistance with an extended half-life compared with GLP-1.

    In plain wordsIn lab tests, liraglutide resisted the DPP-IV enzyme better than natural GLP-1 and lasted longer.

    Peptide
    Liraglutide
    Outcome
    IncreaseDPP-IV resistance and half-life
    Study

    n: not reported in source

    Comparator
    GLP-1
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Liraglutide lacking the gamma-glutamyl linker (Lira-gammaGlu) and Liraglutide exhibited enhanced DPP-IV resistance with extension of t(1/2)

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.